Fuling Technology
001356
KLT
831689
Hand Enterprise Solutions
300170
4
GRANDTECH
835184
5
Doushen(Beijing) Education & Technology Inc.
300010
US Stock MarketDetailed Quotes
NRIX Nurix Therapeutics
- 19.960
- +0.280+1.42%
Close Jan 23 16:00 ET
- 19.900
- -0.060-0.30%
Post 16:49 ET
1.41BMarket Cap-6.88P/E (TTM)
20.100High19.380Low519.88KVolume19.490Open19.680Pre Close10.30MTurnover0.90%Turnover RatioLossP/E (Static)70.84MShares29.56052wk High3.75P/B1.15BFloat Cap7.65052wk Low--Dividend TTM57.74MShs Float52.380Historical High--Div YieldTTM3.66%Amplitude4.220Historical Low19.820Avg Price1Lot Size
About Nurix Therapeutics Company
Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company. It engages in the business of discovering, developing, and commercializing innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. The company was founded by John Kuriyan, Michael Rapé, and Arthur Weiss in 2009 and is headquartered in San Francisco, CA.
Company Profile
SymbolNRIX
Company NameNurix Therapeutics
Listing DateJul 24, 2020
Issue Price19.00
Founded2009
CEODr. Arthur T. Sands, M.D.,PhD
MarketNASDAQ
Employees284
Fiscal Year Ends11-30
Address1700 Owens Street,Suite 205
CitySan Francisco
ProvinceCalifornia
CountryUnited States of America
Zip Code94158
Phone1-415-660-5320
Websitehttp://www.nurixtx.com
Company Executives
- Name
- Position
- Salary
- Dr. Arthur T. Sands, M.D.,PhD
- Director, President and Chief Executive Officer
- 4.36M
- Dr. Christine Ring, J.D.,PhD
- Chief Legal Officer, Chief Compliance Officer and Secretary
- --
- Hans van Houte
- Chief Financial Officer and Principal Accounting Officer
- 1.61M
- Dr. Gwenn Hansen, PhD
- Chief Scientific Officer
- 1.63M
- Dr. David L. Lacey, M.D.
- Chairman of the Board
- 263.29K
- Anil Kapur
- Director
- --
- Julia P. Gregory
- Independent Director
- 238.29K
- Dr. Lori Anne Kunkel, M.D.
- Independent Director
- 228.29K
- Judith A. Reinsdorf, J.D.
- Independent Director
- 225.79K
- Paul M. Silva
- Independent Director
- 225.79K
- Edward C. Saltzman
- Independent Director
- 223.29K
Trending Stocks
Investment Course
Top 5 Industries for Stock Trading under Trump's Second Term
Stocks & Industries to Watch Under Trump's Second Presidency
With mooomoo, find out which stocks and industries may benefit from Trump's second presidency, based on his first administration's track record.
Stocks & Industries to Watch Under Trump's Second Presidency
Key takeaways Tech stocks underwent substantial growth due to tax cuts and reduced corporate regulations in Trump's first term along with defense and aerospace
Discussing
Trump 2.0 Era: What's the next opportunity in the markets?
▪️Could Trump's crypto policies potentially benefit the crypto market? ▪️Might his tariff policies have a positive effect on Chinese stocks
Michael McCarthy CCO
Jan 3 11:57
Ask a strategist - Trump's first day